By Mill Chart
Last update: May 17, 2025
EXELIXIS INC (NASDAQ:EXEL) has been identified as a high-growth momentum stock that also aligns with Mark Minervini’s Trend Template criteria. The company, focused on developing oncology treatments, demonstrates both technical strength and robust fundamental growth, making it a compelling candidate for investors seeking high-growth opportunities.
Minervini’s strategy emphasizes stocks in strong uptrends with clear technical strength. EXEL meets these criteria:
Price Above Key Moving Averages:
Upward-Trending Moving Averages:
Strong Relative Strength:
Price Near 52-Week High:
Beyond technicals, EXEL exhibits strong growth metrics:
Earnings Growth:
Revenue Expansion:
Profitability Improvements:
Analyst Confidence:
EXEL’s technical rating of 10/10 reflects its strong uptrend, high relative strength, and consistent performance. However, the setup rating of 2/10 suggests the stock may be extended in the short term, indicating a potential consolidation before another breakout.
For a deeper technical analysis, review the full EXEL technical report.
Our High Growth Momentum + Trend Template screener lists more stocks meeting these criteria.
This is not investment advice. Always conduct your own research before making investment decisions.
45.4
-0.86 (-1.86%)
Find more stocks in the Stock Screener
EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before considering an investment.
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.